Literature DB >> 21585334

Cervical squamous intraepithelial lesions among HIV-positive women on antiretroviral therapy in Kenya.

Kevin P McKenzie1, Robyn K Rogers, Julia W Njoroge, Grace John-Stewart, Barbra A Richardson, Nelly R Mugo, Hugo De Vuyst, Ritesh N Pamnani, Farzana S Rana, Danson Warui, Michael H Chung.   

Abstract

BACKGROUND: The prevalence of cervical squamous intraepithelial lesions (SIL) among HIV-infected women on antiretroviral therapy in sub-Saharan Africa has not been well described.
METHODS: HIV-infected women enrolled in an HIV treatment clinic in Nairobi, Kenya were offered free cervical screening with Papanicolaou (Pap) smear testing if they were 30 to 39 years of age and on antiretroviral therapy. Women with SIL were compared to those without SIL with univariate analyses and logistic regression.
RESULTS: Of 595 eligible women, 267 accepted Pap testing and had available cytology results, of whom 258 (97%) were on a non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimen. Median duration of antiretroviral therapy was 13 months [interquartile range (IQR), 8-19]. Abnormal cytology was found in 123 women (46%) with 70 women (26%) having low grade squamous intraepithelial lesions (LSIL), 22 (8%) high grade squamous intraepithelial lesions (HSIL), 30(11%) atypical squamous cells of unknown significance (ASCUS) and 1 (0.4%) atypical glandular cells (AGC). Women with SIL had lower median CD4 cell count (239 vs 287 cells/mm3; P=0.02), lower income (<70 USD per month: 57% vs 38%; P=0.01), and less regular condom use (24% vs 40%; P=0.02) compared to those with no SIL. Duration and type of antiretroviral regimen were not significantly associated with SIL.
CONCLUSION: SIL is prevalent among women on antiretroviral therapy and is associated with immunosuppression, low income, and less frequent condom use. Cervical cancer screening and counseling on condom use should be routinely offered to HIV-infected women in antiretroviral treatment clinics in Africa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21585334     DOI: 10.2174/157016211795945214

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  5 in total

1.  Comparison of conventional cervical cytology versus visual inspection with acetic acid among human immunodeficiency virus-infected women in Western Kenya.

Authors:  Hillary Mabeya; Kareem Khozaim; Tao Liu; Omenge Orango; David Chumba; Latha Pisharodi; Jane Carter; Susan Cu-Uvin
Journal:  J Low Genit Tract Dis       Date:  2012-04       Impact factor: 1.925

2.  Outcomes Up to 12 Months After Treatment With Loop Electrosurgical Excision Procedure for Cervical Intraepithelial Neoplasia Among HIV-Infected Women.

Authors:  Megan J Huchko; Hannah Leslie; May Maloba; Jennifer Zakaras; Elizabeth Bukusi; Craig R Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

3.  Epidemiology of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women.

Authors:  Dorcas Obiri-Yeboah; Patrick K Akakpo; Mohamed Mutocheluh; Emmanuel Adjei-Danso; Gloria Allornuvor; Daniel Amoako-Sakyi; Yaw Adu-Sarkodie; Philippe Mayaud
Journal:  BMC Cancer       Date:  2017-10-16       Impact factor: 4.430

Review 4.  Associations between highly active antiretroviral therapy and the presence of HPV, premalignant and malignant cervical lesions in sub-Saharan Africa, a systematic review: current evidence and directions for future research.

Authors:  Sonia Menon; Rodolfo Rossi; Natasha Zdraveska; Mbabazi Kariisa; Sushama D Acharya; Davy Vanden Broeck; Steven Callens
Journal:  BMJ Open       Date:  2017-08-04       Impact factor: 2.692

5.  The association between HIV infection, antiretroviral therapy and cervical squamous intraepithelial lesions in South Western Nigerian women.

Authors:  Oliver Chukwujekwu Ezechi; Karen Odberg Pettersson; Clement Abu Okolo; Innocent Achaya O Ujah; Per Olof Ostergren
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.